Starpharma Holdings Limited · ASX:SPL
Starpharma — Nanobusiness 2007 Conference
34 slides from Starpharma's conference presentation, Apr 16, 2007
Slide 1: CEO Presentation to Nanobusiness 2007 Conference
@ starpharma CEO Presentation to Nanobusiness 2007 Conference Melbourne; 16 April 2007: Dr Jackie Fairley, CEO of Starpharma Holdings Ltd {ASX:SPL, OTCQX:SPHRY) will be presenting at the Nanobusiness 2007 conference in New York on 16 April 2007. The conference provides a forum for small and large co
Slide 2: Starpharma Holdings Limited Investor Presentation
starpharma AERIS PE, OTCOMSP HRY Starpharma Holdings Limited lavestor Presentation April @Oo? Dr Jackie Pairley CEO
Slide 3: starpharma
o starpharma This document contains certain forward-looking statements, relating to Starpbharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “
Slide 4: Outline
o OQuéline starpharma » Investment Highlights and Company Overview « VivaGel™ and Line Extensions » Product Pipeline * Conclusion
Slide 5: Company Overview
Gompany Overview o starpharma » World leader in the development of dendrimer nanotechnology products for pharmaceutical and life- sciences » Lead product VivaGel™ is being developed (under IND) as a microbicide to prevent HIV and Genital Herpes - US$20.3m NIH contract to develop VivaGel™ for HIV - F
Slide 6: Company Structure
o Company Structure starpharma 100% Inc. (ONT) * 36 employees based in Melbourne, Australia * Wholly owned subsidiary based in Michigan, = Leading developer of dendrimers as USA (16 employees) pharmaceuticals * Leading developer and provider of advanced dendrimers for life science & = Lead developme
Slide 7: ADR Program OTCQX:SPHRY and US Shareholding
AOR Program OTCOX:SPHRY and US Shareholding o starpharma * Starparma’s ADR program has been extremely successful since launch in January 2005 -— >72% growth in ADRs issued in 06/07 » ~10.8% of issued capital ® Major brokers include Merrill Lynch, Credit Lyonnais, Natexis Bleichroeder * SPHRY Most he
Slide 8: Starpharma Technology Overview
o Stargeharmar Techaology Overview starpharma Unique Characteristics of Dendrimers: = Precisely defined, synthetic macromolecules (1-10nm) = Precisely defined surface topology = Can be designed to optimize potency, pharmacokinetics and localization; heat stable or biodegradable = High multivalent bi
Slide 9: VivaGel
VivaGe/™ starpharma
Slide 10: VivaGel — Lead Product for Prevention of STIs
o VivaGel™ — Lead Product for Prevention of &Tis stargharma » VivaGel™is a vaginal microbicide being developed to prevent sexually transmitted infections in women - Currently being developed under two INDs for the prevention of HIV and genital herpes =» Gel-based formulation with a nanotech active (
Slide 11: Commercial Opportunity for Microbicides
o Commercial OQoportunity for Microbicides starpharma sd Large, addressable markets Estimated Market for microbicides in — HIV primarily in developing countries Beveloped Countries - HSV-2 in both developing and developed countries ol Use Per isla = Increasing market support for products oe oe a oe
Slide 12: Payor Demand - HIV and HSV-2 Prevention
& Payor Demand - HIV and HSV-2 Prevertion starpharma Source: Microbicide Development Act 2005: US Senate Time to Translate New Knowledge into Practice: A Call for a National Genital Herpes Control Program Edward W. Hook’ and Peter Leane™ “University of Alabama at Birmingham and “Jetfersen County Dep
Slide 13: VivaGel — Product Features and Performance
VivaGel"™ —- Product Features and Performance o starpharma | Extensions Market research indicates international user and payor demand for microbicide gels Compelling HSV-2 &HIV efficacy; non-irritant Contraceptive activity (in animals) Human trials (IND): VivaGel™ is non-toxic and non-irritating Pot
Slide 14: VivaGel — Development and Commercial Strategy
o VivaGer™ —- Development and Commercial Strategy starpharma + One of the most advanced 24 generation microbicides for HIV&HSV « Significant non-dilutive NIH support + Broad application; chronic-use product + Partnering/commercial strategies likely to differ between developed (OTC/Pharma) markets an
Slide 15: VivaGel Summary
VivaGel™ Summary o starpharma Compelling competitive advantages: HIV&Herpes efficacy; non-irritant; contraceptive activity FDA Fast Track Status for HIV Successfully completed Phase 1 human trial (under IND) Currently in human trials under 2 INDs in Australia, USA and Kenya 3 separate NIH funding in
Slide 16: NIH supported HSV-2 Clinical Program
AUH supperted M&V-2 Clinical Program: VivaGel™ Clinte, Misumurz, Menya starpharma
Slide 17: Product Pipeline
Product Pipeline
Slide 18: Starpharma's Pipeline: Balanced for Risk
o Staraharma’s Pipeline: Balanced for Rist starpharma Prooi of Concept Pharmaceutical & Medical Products VivaGel™ » HSV-2 prevention >» HIV prevention » condoms coating & other line extensions ADME Engineering™ » Therapeutic protein PK optimisation Clinical Trials Drug Delivery - Small Molecules » C
Slide 19: Early Commercial Opportunities
Early Commercial Opportunities o starpharma Marketed Dendrimer PrioFect™ siRNA Materials Science / Products Transfection Reagents Industrial Applications Value Transfection Reagents Capture Current Licensed to EMD 2007 / 08 Horizon Biosciences* Existing product sales and Transfection reagent market:
Slide 20: PrioFect and siRNA transfection
o Privfect™ and siRhtA transtection starpharma Adding siRNA to a cell can “turn off” production of specific cellular proteins “The discovery of RNA interference (RNAI) may weil be one of the transforming events in biology in the past decade” Natute The discovery of RNAi has already had an immense im
Slide 21: PrioFect and siRNA transfection
o Privfect™ and siRhtA transtection starpharma + Enhances uptake of siRNA (and DNA) into cells « 2potential applications: « Research reagent ° l n vivo SIRNA / DNA Charge Association Endocytosis Competitive Advantages z 120 + Superior efficacy through reagent j 1? = size control z n 2 a Fs * Cell-sp
Slide 22: EMD Biosciences Deal for PrioFect
o EMO Biosciences Deal for Priorkect™ starpharma Feb. 2007 - Worldwide exclusive license and supply agreement for PrioFect™ | | _ SIRNA and DNA transfection reagents for ce market _ « DNT will supply EMD Biosciences with Priostar™ proprietary dendrimers for the DNA and siRNA transfection research ma
Slide 23: Partnerships and Collaborators
o Partnerships and Collaborators starpharma ool aborators fi DADE BEHRING |MERCK 1! i) DHARMACON Gobuven afohnen Rereavch ‘recRwon @ avoricn INSTITUTE FOR SOLDIER NANCTEC HNOLGBIES: Collaborators bench 22
Slide 24: Key Investment Highlights
Ntey investment Mightights o starpharma tis Compelling competitive advantages Endorsement from key health agencies: - Significant funding and support received from NIH (>US$20M) - The only microbicide with support for genital herpes HIV and genital herpes at epidemic proportions (Europe ~ 15-20%; US
Slide 25: INTERNATIONAL &
INTERNATIONAL & otc Oo< starpharma Starpharna Moldings Limited AEMS PL OTCOM: SP HRY Market Capitalisation 60 NIH Support 26 Cash on Hand (Mar07) ~10 Further information: www. starptharma.com dachkio Fairey CEO tO1E BES IL27O8
Slide 26: starpharma
starpharma
Slide 27: Key Management
Ney Management o starpharma Dr Jackie Fairley, CEO __ Dr Paul Barrett, VP Business | / DrJeremy Paull, VP _ Development & Rea. Affairs _ | Dr Robert Bers, (Presiden ONT inc, = Ben Rogers, Company | secrelary&CrO _ Nigel Baade,Financial —_ - Gonvcler Over 15 years international business development a
Slide 28: Board of Directors — depth of experience and influence
o Soard of Girectors — deoth of experience and influence starpharma + Major player in corporate Australia: Coles Myer, Fosters Brewings + Pharmaceutical experience at DHA Pharmaceuticals, Abbot Laboratories + Founding CEO of Starpharma + Highly respected industry and government participant + Over 15
Slide 29: VivaGel: Animal Efficacy results
o o 7 iy a ie WVivaGel™: Animal Efficacy results i starp arma SHIV/HIV Protection HSV Protection Combined Results VivaGel™: animals protected from HSV-2 N=@ NG, N Ned Ned 100- =e 100% 2 90% 4 80% gs % a 10% gs 60% Ze 50% SE fe A0% 2 30% 20% 10% 0% 5% w/w 3% w/w Placebo gel PBS . SPL7013 gel SPL7013
Slide 30: VivaGel: Significant Advantages Over Competitors
VivaGelr™ ; Significant Advantages Over Competitors o starp harma Competitor Category | _VivaGel"* Advantages VivaGel™ is the only microbicide being developed to prevent genital herpes. Surfacants/Detergents Ulceration possible No surfactant properties | Potential increased risk of Non-irritant _ in
Slide 31: VivaGel Potent Contraceptive Activity in Rabbits
o VivaGel”™ 2 Potent Contraceptive Activity in Rabiuits stargharma » Recent study has shown that SPL7013, the active ingredient in ; ; ; its VivaGel™, exhibits a potent *oneation of Vaginal Soe an seeelave teraiyin® contraceptive effect in rabbits Active Gel-Treated Rabbits Compared with HEC Control
Slide 32: Portfolio of Opportunities
o Portfolio of Opportunities starpharma 31
Slide 33: Pipeline: Drug Delivery & PK Modification of Protein Therapeutics
@ Pipeline: Drug Delivery & PH Modification of Protein Therapeutics starpharma Plasma concentration-time profile in male SD rats for PEGylated poly-L-lysine dendrimers -~ 100000 £ Zz 3 8 e “ a5 Ly Saal PEG yeaa = e & @ 3 t, = 0.6h 5 10000) og } =~ © t,, = 0.7h E é ® ; 5 @ ty, = 9.5h 2 : Lys,<(PEGs75
Slide 34: RNAi therapeutics
@ ANAT therapeutics starpharma Ph TT AMD & DME anti-inflammatories & anti-infectives Ph 1 2006 (RSV) pandemic flu, spinal cord injury, Parkinson's, cystic fibrosis, hypercholesterolemia, neuropathic pain Ph TL AMD (w/ Allergan) Asthma, RSV, Huntington's, viral hepatitis, diabetes, oncology, dermatol